Treatment of severe, uncontrolled eosinophilic asthma: Where we are heading

References

• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2017. http://www.ginasthma.org [last accessed 9 January 2018].
   Google Scholar
• National Heart, Lung, and Blood Institute. Expert panel report 3: Guidelines for the diagnosis and management of asthma. Bethesda (MD): U.S. Department of Health and Human Services; 2007.
   Google Scholar
• Centers for Disease Control and Prevention. Asthma Facts—CDC's national asthma control program grantees. Atlanta (GA): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2013.
   Google Scholar
• Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res Pract. 2017;3:1. doi: 10.1186/s40733-016-0029-3. PMID: 28078100.
   PubMedGoogle Scholar
• Lotvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, Lemanske RF Jr, Wardlaw AJ, Wenzel SE, Greenberger PA Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127:355–360. doi: 10.1016/j.jaci.2010.11.037. PMID: 21281866.
   PubMed Web of Science ®Google Scholar
• Borish L. The immunology of asthma: asthma phenotypes and their implications for personalized treatment. Ann Allergy Asthma Immunol. 2016;117:108–114. doi: 10.1016/j.anai.2016.04.022. PMID: 27499537.
   PubMed Web of Science ®Google Scholar
• Chipps BE, Zeiger RS, Borish L, Wenzel SE, Yegin A, Hayden ML, Miller DP, Bleecker ER, Simons FE, Szefler SJ, et al. Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol. 2012;130:332–342. e10. doi: 10.1016/j.jaci.2012.04.014. PMID: 22694932.
   PubMed Web of Science ®Google Scholar
• Ray A, Raundhal M, Oriss TB, Ray P, Wenzel SE. Current concepts of severe asthma. J Clin Invest. 2016;126:2394–2403. doi: 10.1172/JCI84144. PMID: 27367183.
   PubMed Web of Science ®Google Scholar
• Luskin AT, Chipps BE, Rasouliyan L, Miller DP, Haselkorn T, Dorenbaum A. Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol Pract. 2014;2:544–552. e1-e2. doi: 10.1016/j.jaip.2014.02.011. PMID: 25213047.
   PubMed Web of Science ®Google Scholar
• Robinson D, Humbert M, Buhl R, Cruz AA, Inoue H, Korom S, Hanania NA, Nair P. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017;47:161–175. doi: 10.1111/cea.12880. PMID: 28036144.
   PubMed Web of Science ®Google Scholar
• Skloot GS. Asthma phenotypes and endotypes: a personalized approach to treatment. Curr Opin Pulm Med. 2016;22:3–9. doi: 10.1097/MCP.0000000000000225. PMID: 26574717.
   PubMed Web of Science ®Google Scholar
• Siroux V, Basagana X, Boudier A, Garcia-Aymerich J, Vesin A, Slama R, Jarvis D, Anto JM, Kauffmann F, Sunyer J. Identifying adult asthma phenotypes using a clustering approach. Eur Respir J. 2011;38:310–317. doi: 10.1183/09031936.00120810. PMID: 21233270.
   PubMed Web of Science ®Google Scholar
• Moore WC, Hastie AT, Li X, Busse WW, Jarjour NN, Wenzel SE, Peters SP, Meyers DA, Bleecker ER, National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol. 2014;133:1557–1563. e5.
   Web of Science ®Google Scholar
• National Heart, Lung, and Blood Institute. National Asthma education and prevention program. Expert panel report 3: Guidelines for the diagnosis and management of asthma. Full report 2007. Bethesda (MD): NHLBI Health Information Center; 2007.
   Google Scholar
• Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–373. doi: 10.1183/09031936.00202013. PMID: 24337046.
   PubMed Web of Science ®Google Scholar
• Miller L, Schuz B, Walters J, Walters EH. Mobile technology interventions for asthma self-management: systematic review and meta-analysis. JMIR Mhealth Uhealth. 2017;5:e57. doi: 10.2196/mhealth.7168. PMID: 28465281.
   PubMed Web of Science ®Google Scholar
• Howard S, Lang A, Sharples S, Shaw D. What are the pros and cons of electronically monitoring inhaler use in asthma? A multistakeholder perspective. BMJ Open Respir Res. 2016;3:e000159. doi: 10.1136/bmjresp-2016-000159. PMID: 27933181.
   PubMed Web of Science ®Google Scholar
• Wechsler ME. Managing asthma in primary care: putting new guideline recommendations into context. Mayo Clin Proc. 2009;84:707–717. doi: 10.4065/84.8.707. PMID: 19648388.
   PubMed Web of Science ®Google Scholar
• Reddel HK, Bateman ED, Becker A, Boulet LP, Cruz AA, Drazen JM, Haahtela T, Hurd SS, Inoue H, de Jongste JC et al. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J. 2015;46:622–639. doi: 10.1183/13993003.00853-2015. PMID: 26206872.
   PubMed Web of Science ®Google Scholar
• Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev. 2016;21:CD011721. doi: 10.1002/14651858.CD011721.pub2.
   PubMedGoogle Scholar
• Bonini M, Scichilone N. Tiotropium in asthma: back to the future of anticholinergic treatment. Clin Mol Allergy. 2017;15:20. doi: 10.1186/s12948-017-0076-1. PMID: 29213218.
   PubMedGoogle Scholar
• Willis JC, Lord GM. Immune biomarkers: the promises and pitfalls of personalized medicine. Nat Rev Immunol. 2015;15:323–329. doi: 10.1038/nri3820. PMID: 25814400.
   PubMed Web of Science ®Google Scholar
• Fahy JV. Type 2 inflammation in asthma–present in most, absent in many. Nat Rev Immunol. 2015;15:57–65. doi: 10.1038/nri3786. PMID: 25534623.
   PubMed Web of Science ®Google Scholar
• Voehringer D, Reese TA, Huang X, Shinkai K, Locksley RM. Type 2 immunity is controlled by IL-4/IL-13 expression in hematopoietic non-eosinophil cells of the innate immune system. J Exp Med. 2006;203:1435–1446. doi: 10.1084/jem.20052448. PMID: 16702603.
   PubMed Web of Science ®Google Scholar
• Chang YJ, Kim HY, Albacker LA, Baumgarth N, McKenzie AN, Smith DE, Dekruyff RH, Umetsu DT. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol. 2011;12:631–638. doi: 10.1038/ni.2045. PMID: 21623379.
   PubMed Web of Science ®Google Scholar
• Carr TF, Berdnikovs S, Simon HU, Bochner BS, Rosenwasser LJ. Eosinophilic bioactivities in severe asthma. World Allergy Organ J. 2016;9:21. doi: 10.1186/s40413-016-0112-5. PMID: 27386041.
   PubMed Web of Science ®Google Scholar
• Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol. 2013;13:9–22. doi: 10.1038/nri3341. PMID: 23154224.
   PubMed Web of Science ®Google Scholar
• George L, Brightling CE. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis. 2016;7:34–51. doi: 10.1177/2040622315609251. PMID: 26770668.
   PubMed Web of Science ®Google Scholar
• Schleich FN, Manise M, Sele J, Henket M, Seidel L, Louis R. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med. 2013;13:11. doi: 10.1186/1471-2466-13-11. PMID: 23442497.
   PubMed Web of Science ®Google Scholar
• Wagener AH, de Nijs SB, Lutter R, Sousa AR, Weersink EJ, Bel EH, Sterk PJ. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 2015;70:115–120. doi: 10.1136/thoraxjnl-2014-205634. PMID: 25422384.
   PubMed Web of Science ®Google Scholar
• Ricciardolo FLM, Silkoff PE. Perspectives on exhaled nitric oxide. J Breath Res. 2017;11:047104. doi: 10.1088/1752-7163/aa7f0e. PMID: 28696336.
   PubMed Web of Science ®Google Scholar
• Wang FP, Liu T, Lan Z, Li SY, Mao H. Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a systematic review and meta-analysis. PLoS One. 2016;11:e0166833. doi: 10.1371/journal.pone.0166833. PMID: 27875559.
   PubMed Web of Science ®Google Scholar
• Cabon Y, Molinari N, Marin G, Vachier I, Gamez AS, Chanez P, Bourdin A. Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials. Clin Exp Allergy. 2017;47:129–138. doi: 10.1111/cea.12853. PMID: 27859832.
   PubMed Web of Science ®Google Scholar
• CINQAIR (reslizumab injection), solution for subcutaneous use [package insert]. Frazer, PA: Teva Respiratory, LLC; 2016
   Google Scholar
• NUCALA (mepolizumab injection), solution for subcutaneous use [package insert]. Philadelphia, PA: GlaxoSmithKline LLC; 2017.
   Google Scholar
• FASENRA™ (benralizumab) [package insert]. Södertälje, Sweden: AstraZeneca AB; 2017.
   Google Scholar
• Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, Reed JL, Woods R, Dall'acqua WW, Stephens GL et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125:1344–1353. e2. doi: 10.1016/j.jaci.2010.04.004. PMID: 20513525.
   PubMed Web of Science ®Google Scholar
• Pham TH, Damera G, Newbold P, Ranade K. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 2016;111:21–29. doi: 10.1016/j.rmed.2016.01.003. PMID: 26775606.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651–659. doi: 10.1016/S0140-6736(12)60988-X. PMID: 22901886.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID; SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189–1197. doi: 10.1056/NEJMoa1403291. PMID: 25199060.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198–1207. doi: 10.1056/NEJMoa1403290. PMID: 25199059.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, Brightling CE, Pavord ID. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4:549–556. doi: 10.1016/S2213-2600(16)30031-5. PMID: 27177493.
   PubMed Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O'Brien C, Korn S. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3:355–366. doi: 10.1016/S2213-2600(15)00042-9. PMID: 25736990.
   PubMed Web of Science ®Google Scholar
• Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150:789–798. doi: 10.1016/j.chest.2016.03.032. PMID: 27056586.
   PubMed Web of Science ®Google Scholar
• Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150:799–810. doi: 10.1016/j.chest.2016.03.018. PMID: 27018175.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115–2127. doi: 10.1016/S0140-6736(16)31324-1. PMID: 27609408.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128–2141. doi: 10.1016/S0140-6736(16)31322-8. PMID: 27609406.
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376:2448–2458. doi: 10.1056/NEJMoa1703501. PMID: 28530840.
   PubMed Web of Science ®Google Scholar
• Goldman M, Hirsch I, Zangrilli JG, Newbold P, Xu X. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies. Curr Med Res Opin. 2017;33:1605–1613. doi: 10.1080/03007995.2017.1347091. PMID: 28644104.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, Newbold P, Goldman M. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2017;S2213–S2600:30344–2.
   Google Scholar
• Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167:199–204. doi: 10.1164/rccm.200208-789OC. PMID: 12406833.
   PubMed Web of Science ®Google Scholar
• Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, Busse WW, Wenzel S, Wu Y, Datta V et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132:1086–1096. e5.
   Web of Science ®Google Scholar
• de Groot JC, Storm H, Amelink M, de Nijs SB, Eichhorn E, Reitsma BH, Bel EH, Ten Brinke A. Clinical profile of patients with adult-onset eosinophilic asthma. ERJ Open Res. 2016;2. doi: 10.1183/23120541.00100-2015. PMID: 27730197.
   PubMedGoogle Scholar
• Peters MC, Nguyen ML, Dunican EM. Biomarkers of airway type-2 inflammation and integrating complex phenotypes to endotypes in asthma. Curr Allergy Asthma Rep. 2016;16:71. doi: 10.1007/s11882-016-0651-4. PMID: 27613654.
   PubMed Web of Science ®Google Scholar
• Chung KF. Precision medicine in asthma: linking phenotypes to targeted treatments. Curr Opin Pulm Med. 2018;24:4–10. doi: 10.1097/MCP.0000000000000434. PMID: 29036018.
   PubMed Web of Science ®Google Scholar
• Medrek SK, Parulekar AD, Hanania NA. Predictive biomarkers for asthma therapy. Curr Allergy Asthma Rep. 2017;17:69. doi: 10.1007/s11882-017-0739-5. PMID: 28929293.
   PubMed Web of Science ®Google Scholar
• James A, Janson C, Malinovschi A, Holweg C, Alving K, Ono J, Ohta S, Ek A, Middelveld R, Dahlén B et al. Serum periostin relates to type-2 inflammation and lung function in asthma: data from the large population-based cohort Swedish GA(2)LEN. Allergy. 2017;72:1753–1760. doi: 10.1111/all.13181. PMID: 28398635.
   PubMed Web of Science ®Google Scholar
• Shiobara T, Chibana K, Watanabe T, Arai R, Horigane Y, Nakamura Y, Hayashi Y, Shimizu Y, Takemasa A, Ishii Y. Dipeptidyl peptidase-4 is highly expressed in bronchial epithelial cells of untreated asthma and it increases cell proliferation along with fibronectin production in airway constitutive cells. Respir Res. 2016;17:28. doi: 10.1186/s12931-016-0342-7. PMID: 26975422.
   PubMed Web of Science ®Google Scholar
• Panettieri RA Jr. Neutrophilic and pauci-immune phenotypes in severe asthma. Immunol Allergy Clin North Am. 2016;36:569–579. doi: 10.1016/j.iac.2016.03.007. PMID: 27401627.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2018. http://www.ginasthma.org [last accessed 16 March 2018].
   Google Scholar
• XOLAIR (omalizumab injection), solution for subcutaneous use [package insert]. South San Francisco, CA: Genentech, Inc. A Member of the Roche Group; 2017.
   Google Scholar
• Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, Irvin CG, Leigh MW, Lundberg JO, Olin AC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184:602–615. doi: 10.1164/rccm.9120-11ST. PMID: 21885636.
   PubMed Web of Science ®Google Scholar